Literature DB >> 2784457

Soluble CD8 during T cell activation.

B E Tomkinson1, M C Brown, S H Ip, S Carrabis, J L Sullivan.   

Abstract

The CD8 Ag has long been used as a surface marker for the identification of cytotoxic and suppressor cells. Recently CD8-positive cells have been shown to release a soluble form of the CD8 Ag. We have devised a sandwich monoclonal enzyme immunoassay for the quantitation of this released CD8. Soluble CD8 was released in response to lymphocyte activation. In vitro, PHA or anti-CD3 mAb-mediated T cell activation led to release of CD8 into the culture supernatant. In vivo, serum from patients with EBV-induced infectious mononucleosis (IM), a disease associated with intense CD8+ T cell activation, demonstrated elevations in soluble CD8 (7939 U/ml, day 0) compared to serum from normal controls (289 U/ml). Levels of soluble CD8 correlated (r = 0.82, p less than 0.001) with the increased percentage of CD8+/HLA-DR+ (activated CD8+ T cells) observed in acute IM. Sequential analysis of serum during the course of IM shows that soluble CD8 levels parallel the decline in CD8+/HLA-DR+ cells that occurs with the resolution of the disease. These data suggest that released CD8 may be of value in monitoring the involvement of CD8+ T cells in response to a pathologic event. The functional role of the released CD8 molecule will require further investigation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784457

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Serum soluble CD4, CD8 and IL-2R levels in adult acute myeloid leukemia in remission.

Authors:  Y Iizuka; M Aiso; T Ohshima; S Sawada; T Horie
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

2.  Lower concentration of serum soluble CD8 in severe Hashimoto's disease.

Authors:  N Yamamoto; M Watanabe; F Matsuzuka; A Miyauchi; Y Iwatani
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

3.  Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias.

Authors:  S H Lim; C Worman; A Jewell; C Tsakona; F J Giles; A Goldstone
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Serum cytokine profiles in experimental human malaria. Relationship to protection and disease course after challenge.

Authors:  R Harpaz; R Edelman; S S Wasserman; M M Levine; J R Davis; M B Sztein
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

5.  High serum levels of CD8 antigen in primary biliary cirrhosis: a possible cause of suppressor cell dysfunction?

Authors:  K T Nouri Aria; M Lombard; R Williams
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

6.  Poor induction of interleukin-2 receptor expression on CD8bright+ cells in whole blood cell cultures with CD3 mAb. Implications for immunotherapy with CD3 mAb.

Authors:  R A Janssen; A A Heijn; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

7.  CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma.

Authors:  G C de Gast; I A Haagen; A A van Houten; S C Klein; A J Duits; R A de Weger; T M Vroom; M R Clark; J Phillips; A J van Dijk
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968

8.  Soluble CD4 and CD8 in serum from patients with localized scleroderma.

Authors:  S Sato; M Fujimoto; K Kikuchi; H Ihn; K Tamaki; K Takehara
Journal:  Arch Dermatol Res       Date:  1996-06       Impact factor: 3.017

9.  B cell activation in clinically quiescent systemic lupus erythematosus (SLE) is related to immunoglobulin levels, but not to levels of anti-dsDNA, nor to concurrent T cell activation.

Authors:  P E Spronk; B T vd Gun; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

10.  High serum levels of soluble CD8 in insulin-dependent diabetes.

Authors:  E Di Cesare; M Previti; M C Ingemi; G F Bagnato; D Cucinotta
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.